Ultrainvest med - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 15,434 | 41,928 | 153,496 | 449,652 | 445,881 | 719,194 | 1,626,560 | 2,509,320 |
| Profit before tax | 17,502 | - | - | - | - | - | 18,786 | 16,967 |
| Net profit | 16,627 | 2,920 | -69,927 | 60,242 | 46,147 | 23,697 | 16,659 | 14,745 |
| Equity | 40,204 | 43,124 | -29,723 | 30,519 | 76,667 | 100,364 | 117,023 | 127,972 |
| Liabilities | 50,120 | 68,155 | 97,295 | 480,096 | 563,224 | 621,424 | 621,457 | 745,034 |
| Non-current assets | 57,597 | 59,055 | 14,596 | 227,076 | 307,029 | 343,848 | 362,636 | 570,065 |
| Current assets | 32,727 | 52,224 | 52,976 | 283,539 | 332,862 | 377,940 | 375,844 | 302,941 |
| Total assets | 90,324 | 111,279 | 67,572 | 510,615 | 639,891 | 721,788 | 738,480 | 873,006 |
|
Taxes paid
|
||||||||
| Social insurance contributions | - | - | - | - | - | 19,933 | 23,195 | 19,353 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +196.5% | +171.7% | +266.1% | +192.9% | -0.8% | +61.3% | +126.2% | +54.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 18.4% | 2.6% | -103.5% | 11.8% | 7.2% | 3.3% | 2.3% | 1.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 41.4% | 6.8% | - | 197.4% | 60.2% | 23.6% | 14.2% | 11.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 107.7% | 7.0% | -45.6% | 13.4% | 10.3% | 3.3% | 1.0% | 0.6% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 113.4% | - | - | - | - | - | 1.2% | 0.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.2 | 1.6 | - | 15.7 | 7.3 | 6.2 | 5.3 | 5.8 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 15,434 | 41,928 | 153,496 | 128,472 | 54,597 | 91,812 | 232,366 | 418,220 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Ultrainvest med - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-11 | 2026-05-12 | 2.43 |
| 2026-01-16 | 2026-01-26 | 853.40 |
| 2025-09-16 | 2025-09-16 | 972.99 |
| 2025-08-28 | 2025-08-29 | 1098.16 |
| 2025-08-19 | 2025-08-26 | 1098.16 |
| 2025-05-16 | 2025-05-21 | 1914.07 |
| 2025-03-18 | 2025-03-24 | 1726.62 |
| 2024-10-16 | 2024-10-17 | 1997.64 |
| 2024-07-16 | 2024-07-16 | 1803.22 |
| 2024-04-16 | 2024-04-28 | 115.37 |
| 2024-03-18 | 2024-04-04 | 142.40 |
| 2024-02-19 | 2024-02-22 | 30.30 |
| 2024-01-16 | 2024-02-11 | 31.04 |
| 2023-11-16 | 2023-11-28 | 122.95 |
| 2023-10-17 | 2023-11-08 | 23.68 |
| 2023-09-18 | 2023-10-05 | 23.25 |
| 2023-08-17 | 2023-09-11 | 23.53 |
| 2023-03-16 | 2023-03-16 | 2197.11 |
| 2023-01-17 | 2023-01-17 | 1478.38 |
| 2022-09-16 | 2022-09-18 | 1609.93 |
| 2022-06-16 | 2022-06-16 | 1389.15 |
| 2021-12-16 | 2021-12-16 | 1525.93 |
| 2021-11-16 | 2021-11-16 | 1250.28 |
| 2021-09-16 | 2021-09-26 | 1160.82 |
Ultrainvest med - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-04-28 | 2025-04-28 | 23538.96 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Ultrainvest med, UAB (code 301700834) is a Private Limited Liability Company active in the wholesale of pharmaceutical and medical goods. In financial year 2025, the company generated revenue of €2.51M, up 54.3% year on year and 248.9% over two years. Net profit was €14.7K, compared with €16.7K in 2024 and €23.7K in 2023, so profitability has weakened as turnover expanded. The 2025 profit margin was 0.6%. At year-end, total assets stood at €873.0K, equity at €128.0K and liabilities at €745.0K, indicating a leveraged balance sheet with an equity ratio of 14.7% and debt-to-equity of 5.82. Return on equity was 11.5% and return on assets 1.7%, while asset turnover reached 2.87x. Revenue per employee was €418.2K and profit per employee €2.5K, pointing to high sales intensity but modest earnings conversion.